PMID- 22987983
OWN - NLM
STAT- MEDLINE
DCOM- 20130426
LR  - 20201215
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 23 Suppl 10
DP  - 2012 Sep
TI  - Prevention and handling of acute allergic and infusion reactions in oncology.
PG  - x313-9
AB  - Drug hypersensitivity reactions (HSR) are adverse events resembling allergy which 
      occur at therapeutic doses. Both anticancer chemotherapeutics and monoclonal 
      antibodies have the potential for acute HSR. all infusion reactions involve the 
      immune system; however, some (anaphylactic) are allergic in nature and usually 
      are mediated by immunoglobulin E (IgE), whereas others (anaphylactoid) are not 
      true allergic reactions and are not mediated by IgE. although HSR can be allergic 
      or nonallergic, the clinical manifestations are the same and require prompt, 
      accurate assessment and management to avoid severe adverse events, including 
      fatality. Monoclonal antibodies have a unique side-effect profile that includes 
      the potential for nonallergic HSR caused by cytokine release. Chemotherapeutic 
      agents with the highest potential for acute HSR include the platinum salts, 
      taxanes, procarbazine, asparaginase and the epipodophyllotoxins. From all 
      anticancer agents, rituximab causes the majority of HSR (27%), followed by 
      paclitaxel (10%). The most frequent symptoms in patients experiencing acute HSR 
      include chest pain, dyspnea, wheezing and exanthema for the taxanes, dyspnea and 
      exanthema for platinum salts, chills and rigor for antibodies. Patients with 
      mild-to-moderate acute HSR can be rechallenged following intensified prophylaxis, 
      but rechallenge is usually not recommended following severe HSR.
FAU - Joerger, M
AU  - Joerger M
AD  - Department of Oncology and Hematology, Cantonal Hospital, St Gallen, Switzerland. 
      markus.joerger@gmail.com
LA  - eng
PT  - Congress
PT  - Overall
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Taxoids)
RN  - 35S93Y190K (Procarbazine)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 49DFR088MY (Platinum)
RN  - EC 3.5.1.1 (Asparaginase)
RN  - L36H50F353 (Podophyllotoxin)
SB  - IM
MH  - *Anaphylaxis/chemically induced/etiology/prevention & control
MH  - Antibodies, Monoclonal/adverse effects/therapeutic use
MH  - Asparaginase/adverse effects/therapeutic use
MH  - *Drug Hypersensitivity/immunology/prevention & control
MH  - Humans
MH  - *Immunoglobulin E/immunology/metabolism
MH  - *Neoplasms/complications/drug therapy
MH  - Platinum/adverse effects/therapeutic use
MH  - Podophyllotoxin/adverse effects/therapeutic use
MH  - Procarbazine/adverse effects/therapeutic use
MH  - Taxoids/adverse effects/therapeutic use
EDAT- 2012/09/26 06:00
MHDA- 2013/04/27 06:00
CRDT- 2012/09/19 06:00
PHST- 2012/09/19 06:00 [entrez]
PHST- 2012/09/26 06:00 [pubmed]
PHST- 2013/04/27 06:00 [medline]
AID - S0923-7534(19)41767-5 [pii]
AID - 10.1093/annonc/mds314 [doi]
PST - ppublish
SO  - Ann Oncol. 2012 Sep;23 Suppl 10:x313-9. doi: 10.1093/annonc/mds314.